MAPT and Alzheimer disease: Using Gallyas–Braak's silver impregnation and tau and Aβ immunostaining, we applied Braak’s staging for neurofibrillary changes (stages I to VI) and senile plaques (stages A to C) for the evaluation of AD-related pathology [23,24].